<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>High-flow hemodialysis arteriovenous access</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">High-flow hemodialysis arteriovenous access</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">High-flow hemodialysis arteriovenous access</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald A Beathard, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen D Dillavou, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ingemar Davidson, MD, PhD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1408496829"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Arteriovenous (AV) vascular access is necessary for the delivery of lifesaving hemodialysis therapy but is nonphysiologic and harmful with considerable downsides [<a href="#rid1">1</a>]. AV hemodialysis access exerts an adverse effect on the heart because of the increased workload demanded by the vascular access blood flow (Qa) [<a href="#rid2">2</a>]. Although this is superimposed upon the cardiopulmonary dysfunction that develops in patients with chronic kidney disease, in the absence of a pre-existing clinically significant comorbidity (heart disease, pulmonary hypertension, severe microvascular disease), it is generally tolerated [<a href="#rid3">3-6</a>]. However, Qa can reach levels that can generate adverse sequelae, some of which can be life-threatening. Early recognition and management of the inappropriately high-flow AV access is an important aspect of medical care delivered to the hemodialysis patient.</p><p>The clinical features, diagnosis, and management of the high-flow AV access are reviewed. Other complications related to AV access are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a>.)</p><p class="headingAnchor" id="H1196050188"><span class="h1">HIGH-FLOW ARTERIOVENOUS ACCESS</span></p><p class="headingAnchor" id="H1179621480"><span class="h2">Definition</span><span class="headingEndMark"> — </span>To define hemodialysis arteriovenous (AV) access flow (Qa), one must first define normal access Qa. Unfortunately, there is no generally accepted definition for either of these. Ideally, Qa would be the minimum that is adequate for efficient hemodialysis while still maintaining AV access patency. A physiologically mature AV fistula has been defined as having a Qa of 500 mL/min or greater [<a href="#rid7">7</a>]. </p><p>Under normal circumstances, AV access blood flow is greater for a brachial artery-based AV fistula compared with a distal radial-cephalic AV fistula [<a href="#rid8">8-10</a>]. Studies documenting AV access blood flow rates in asymptomatic patients have reported values ranging from 785 to 998 mL/min in radial-cephalic AV fistulas [<a href="#rid6">6,8-14</a>] and from 1376 to 1580 mL/min in brachial-cephalic AV fistulas [<a href="#rid8">8,9</a>]. According to a survey conducted by the US Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor, the mean Qa prescribed by surveyed facilities was 417 mL/min (median 400 mL/min) [<a href="#rid15">15</a>]. For effective dialysis, Qa should exceed this level by at least 100 mL/min. When blood flow has been reduced to levels no lower than 500 to 600 mL/min for AV fistulas and 600 to 700 mL/min for AV grafts, post-banding access patency rates have been reasonably good [<a href="#rid16">16,17</a>]. (See <a class="local">'Target flow rate'</a> below.)</p><p>Although the exact threshold for defining a high-flow Qa access has not been rigorously validated nor universally accepted, a Qa of 1500 mL/min, or Qa &gt;20 percent of the cardiac output (ie, cardiopulmonary recirculation [CPR] &gt;20 percent) has been suggested [<a href="#rid3">3,15,18</a>]. It should be noted, however, that patients with specifically related comorbidities can develop adverse sequelae from a Qa below this level. In this sense, there is an element of individuality intrinsic to the definition of excessive high flow. </p><p class="headingAnchor" id="H3903395984"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>High Qa is more commonly seen in association with an AV fistula than with an AV graft. Blood flow in an AV graft is maximal at the time of creation, and there is less of a tendency towards an increase in blood flow with the passage of time. By contrast, with an AV fistula, Qa increases rapidly during the first weeks to months after creation [<a href="#rid10">10</a>]. The blood flow rate in the access continues to increase but at a slower rate as the AV fistula ages. In some cases, it can reach levels in excess of 4000 mL/min [<a href="#rid19">19</a>].</p><p>An AV fistula associated with a larger artery (and vein) is at greater risk for the development of a high blood flow rate [<a href="#rid20">20</a>]. This being the case, brachial-cephalic and brachial-basilic accesses are much more commonly associated with this problem than a distal radial-cephalic access [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3159331692"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>There is no level of access flow volume that is without some degree of adverse physiologic consequences. While an excessively high blood flow rate (Qa) is associated with adverse sequelae, the ability to tolerate high AV access flow is variable. </p><p>The clinical manifestations associated with a high-flow hemodialysis AV access can range from an asymptomatic incidental finding to a severe, life-threatening situation. Discussions concerning this problem generally focus on conditions such as heart failure, pulmonary hypertension, and hand ischemia; however, other problems can also occur requiring attention. These are reviewed briefly below and in more detail in associated topics.</p><p class="headingAnchor" id="H4051786664"><span class="h2">Cardiopulmonary</span></p><p class="headingAnchor" id="H1530924432"><span class="h3">Eccentric left ventricular hypertrophy</span><span class="headingEndMark"> — </span>Left ventricular hypertrophy (LVH) is highly prevalent among patients with end-stage kidney disease and is a strong predictor of morbidity and mortality [<a href="#rid4">4,22,23</a>]. The creation of an AV access is accompanied by an increase in cardiac output, the degree of which is directly proportional to the Qa. This is accompanied by an expansion of blood volume leading to increased venous return and right atrial, pulmonary artery, and left ventricular end-diastolic pressures [<a href="#rid24">24-26</a>]. Both plasma atrial natriuretic peptide and brain natriuretic peptide concentrations increase, peaking 10 days after AV fistula creation, consistent with the presence of cardiac volume overload [<a href="#rid27">27</a>]. </p><p>The chronic effects of these changes on the myocardium appear to be due primarily to volume overload, which translates into a remodeling of the cardiac muscle. This is characterized by four-chamber dilatation and what is referred to as eccentric left LVH, the development of which is proportional to the Qa [<a href="#rid2">2,28</a>]. This is distinguished from concentric LVH in which the pathogenic mechanism is a pressure overload resulting in muscle hypertrophy. In both cases, an increase in left ventricular muscle mass occurs, but with eccentric LVH, a relatively normal wall thickness is maintained, while wall thickening occurs with concentric LVH  (<a class="graphic graphic_figure graphicRef138626" href="/d/graphic/138626.html" rel="external">figure 1</a>) [<a href="#rid24">24</a>]. In one study involving predialysis patients, the incidence of LVH following AV fistula creation increased from 67 percent at baseline to 83 and 90 percent at one and three months, respectively [<a href="#rid29">29</a>]. This increase was due to the development of eccentric LVH.</p><p class="headingAnchor" id="H933632915"><span class="h3">High-output cardiac failure</span><span class="headingEndMark"> — </span>Heart failure is a serious problem for patients with end-stage kidney disease (ESKD). Approximately 35 to 40 percent of patients with chronic kidney disease have an established diagnosis of heart failure at initiation of hemodialysis. An estimated 44 percent of patients on hemodialysis have heart failure, and cardiac disease is the most common cause of death in the dialysis patient [<a href="#rid5">5,6</a>].</p><p>The creation of an AV access increases cardiac output. As Qa increases over time with an AV fistula, it can eventually exceed the patient's cardiac functional reserve resulting in high-output cardiac failure (HOCF) [<a href="#rid30">30-33</a>]. Although this is more likely to occur at a lower Qa in patients with preexisting heart disease, even without cardiovascular disease, an excessively high Qa can adversely affect cardiac output, leading to HOCF. (See  <a class="medical medical_review" href="/d/html/3462.html" rel="external">"Causes and pathophysiology of high-output heart failure", section on 'Arteriovenous fistula'</a>.)</p><p>HOCF is characterized by dyspnea either at rest or with varying degrees of exertion, orthopnea, paroxysmal nocturnal dyspnea, and edema (pulmonary, peripheral) in the presence of an above-normal cardiac index or simply an elevated cardiac output [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/d/html/113041.html" rel="external">"Clinical manifestations, diagnosis, and management of high-output heart failure"</a>.)</p><p>Because of the high incidence of heart failure in patients with chronic kidney disease, in general, and the fact that the signs and symptoms suggesting this diagnosis are often obscured by the effects of ultrafiltration during the dialysis treatment in reducing fluid and maintaining a dry weight, it is important to have a high index of suspicion for the development of HOCF [<a href="#rid36">36</a>]. Patients with intractable or worsening symptoms despite maximum medical management should undergo assessment for HOCF. (See  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a>.)</p><p class="headingAnchor" id="H2198353307"><span class="h3">Myocardial ischemia</span><span class="headingEndMark"> — </span>Cardiovascular disease accounts for &gt;40 percent of deaths in patients with ESKD. Atherosclerotic coronary heart disease is a large proportion of the cardiovascular disease spectrum in these patients, with the prevalence being several-fold greater than in age-matched subjects without kidney disease [<a href="#rid37">37</a>]. This high incidence is driven in large part by a clustering of traditional risk factors such as hypertension, diabetes, and age. The cardiac changes occurring with the creation of an AV access predispose the patient to an increased risk for myocardial ischemia caused by an adverse imbalance between subendocardial oxygen supply and increased oxygen demand consequent to the increased cardiac output. One study used pulse wave analysis to determine the subendocardial viability ratio (SEVR; ratio of the area under the diastolic aortic pressure curve to the area under the systolic aortic pressure curve) in a group of patients before and after AV fistula creation [<a href="#rid25">25</a>]. SEVR was used to gauge the relationship between myocardial oxygen supply and demand. Following AV fistula creation, SEVR immediately decreased and remained low throughout the six-month study period, implying a significant impact on subendocardial perfusion. A high-flow AV access predisposes to further increased risk for myocardial ischemia caused by an adverse imbalance between subendocardial oxygen supply and increased oxygen demand consequent to a greater cardiac output [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3461592036"><span class="h3">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Increased AV flow over time in the setting of altered cardiovascular physiology or pathology may also contribute to the increased risk of developing pulmonary hypertension in patients with ESKD [<a href="#rid39">39</a>]. The increase in cardiac output following AV access creation is accompanied by an increase in pulmonary arterial pressure, which correlates with Qa [<a href="#rid11">11,26,40</a>]. This change can be attenuated or resolve in some patients by AV access compression or closure [<a href="#rid12">12,26,41-46</a>]. </p><p>Pulmonary hypertension is characterized by symptoms of progressive dyspnea, fatigue, syncope, and signs of right heart failure. A high index of suspicion for the development of pulmonary hypertension is critical; patients with intractable or worsening symptoms should undergo assessment for high Qa. The clinical features and diagnosis of pulmonary hypertension are provided separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/112442.html" rel="external">"Pulmonary hypertension in patients with end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H379136574"><span class="h2">Hemodialysis access-induced distal ischemia</span><span class="headingEndMark"> — </span>Ischemic complications of hemodialysis AV access are uncommon but can result in significant limb dysfunction or even limb loss. Hemodialysis access-induced distal ischemia (HAIDI) occurs due to decreased perfusion pressure occurring distal to the AV access anastomosis. In most cases, compensatory mechanisms counteract this adverse effect; however, in cases where this is inadequate, hand ischemia results and can lead to gangrene and digit loss. Although Qa in these cases may be low, normal, or high, most cases are characterized by a high Qa. (See  <a class="medical medical_review" href="/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia"</a>.)</p><p class="headingAnchor" id="H3654239407"><span class="h2">Decreased dialysis clearance secondary to high cardiopulmonary recirculation</span><span class="headingEndMark"> — </span>An excessively high Qa can have an adverse effect efficiency of dialysis because of a high level of cardiopulmonary recirculation (CPR) [<a href="#rid47">47</a>]. CPR is characterized by dialyzed blood returning to the dialyzer after traversing the cardiopulmonary circulation. A fraction of this volume that returns to the AV access has a lower blood urea nitrogen (BUN) concentration when compared with the peripheral venous BUN because it has not traversed the BUN-rich systemic microcirculation. Because of this phenomenon, blood at the dialyzer inlet has a BUN concentration lower than that of systemic venous blood, and the quantity cleared is less. A high Qa relative to cardiac output enhances CPR and can adversely affect the efficiency of the dialysis treatment [<a href="#rid48">48</a>]. Dialysis efficiency is reduced by an amount roughly equal to the ratio of CPR to cardiac output [<a href="#rid48">48-50</a>]. A fistula with a Qa of 1 L/minute will have approximately 17 percent of the cardiac output that bypasses the systemic microcirculation, while a fistula with a Qa of 2.3 L/minute will have 27 percent of the cardiac output that evades the systemic microcirculation during dialysis [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H4068274932"><span class="h2">Accelerated central or peripheral venous stenosis</span><span class="headingEndMark"> — </span>The most common complication associated with an AV access is venous outflow stenosis. This is the result of neointimal hyperplasia resulting from an adverse response of the endothelium of the vessel to a derangement in the hemodynamics of blood flow [<a href="#rid51">51,52</a>]. These lesions occur at specific sites, the anatomy of which promotes turbulent blood flow resulting in a derangement in wall shear stress. Susceptible sites include points where vessels branch, venous valves, sharply angled curved zones within the vessel, and areas of compliance mismatch. This process has a linear relationship to blood flow velocity and volume [<a href="#rid51">51,52</a>]. With the development of stenosis, blood flow through that zone increases in velocity, resulting in propagation of the stenotic lesion. Specific lesions associated with hemodialysis AV access are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access", section on 'Specific AV access lesions'</a>.).</p><p>It is not clear as to whether an excessively high Qa can also promote the development of stenosis in the central veins. This mechanism has been perceived to be the culprit in patients in whom a history of prior hemodialysis catheter placement was lacking, with a prevalence between 5 and 10 percent [<a href="#rid53">53,54</a>]. In a study of 57 hemodialysis patients [<a href="#rid54">54</a>], six (10 percent) had symptomatic de novo central vein stenosis. All six patients had massive swelling of their access arm. The access was located at the elbow in five and at the wrist in one case. Three cases had stenosis of the left subclavian vein, and three had stenosis of the left brachiocephalic vein. In the four patients in whom it was available, the mean access blood flow volume was 2347 mL/min. It has also been suggested that a high Qa from an associated AV access in a patient with a central venous catheter can increase the risk for the development of central venous stenosis. Central vein stenosis has been reported in the absence of any antecedent. In a study of 69 hemodialysis patients in whom an angiogram was done in preparation for dialysis catheter insertion, 14 of 46 (30 percent) had no antecedent central venous intervention and were found to have significant stenosis involving the venous structures through which the catheter would pass [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access"</a> and  <a class="medical medical_review" href="/d/html/1957.html" rel="external">"Failure of the mature hemodialysis arteriovenous fistula", section on 'Stenotic vascular lesions'</a>.)</p><p class="headingAnchor" id="H1350986048"><span class="h2">Aneurysmal enlargement of the AV access</span><span class="headingEndMark"> — </span>The increase in blood flow at the time of AV fistula creation results in a proportional increase in wall shear stress. This promotes the secretion of mediators that promote vasodilatation and remodeling of the vein. The result is an increase in the diameter of the vessel restoring shear stress to baseline levels. This sequence of events has a linear relationship with blood flow velocity and volume [<a href="#rid51">51,52</a>]. With excessively high Qa, progressive remodeling of the vessel results in progressive enlargement of the AV fistula, reaching a size significantly greater than occurs with lower levels of Qa. The possible development of downstream venous stenosis, also promoted by an excessively high Qa, has an additive effect on vessel enlargement due to increased pressure within the vein. If allowed to progress unabated, the end result can be a diffusely ectatic, tortuous AV fistula commonly referred to as a "megafistula"  (<a class="graphic graphic_picture graphicRef134591" href="/d/graphic/134591.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef117563" href="/d/graphic/117563.html" rel="external">picture 2</a>).</p><p>The effects of hypervolemic pressure associated with excessively high Qa invoke the principles of Laplace Law, which defines the relationship between wall tension and both pressure and size (radius). This relationship is such that either an increase in size, an increase in pressure, or both will result in an increase in wall tension. Under normal circumstances, the vessel responds to this increase in tension by wall thickening. As a result, the process of vessel enlargement tends to be uniform except in areas where the vein is injured by repetitive cannulation. Frequently, thickening does not occur in these areas. The vessel wall in that zone becomes progressively thinner, creating a weak area in the access. This tends to bulge, resulting in aneurysmal dilatation. Development of an associated downstream venous stenosis can aggravate this process. Repetitive injury to the site eventually results in replacement of healthy tissue with scar formation. Pressure within the aneurysm increases progressively as the aneurysm enlarges because of Bernoulli principle, which states that a decrease in the velocity of the flow of the fluid results in higher pressures. In other words, with the blood flow through the access being constant, flow through the larger diameter of the aneurysm results in a lower velocity, creating higher pressure within that zone. As a result, there is a tendency for the aneurysm to continue to increase in size over time. The tendency for this process to occur has a linear relationship with Qa. (See  <a class="medical medical_review" href="/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications", section on 'Aneurysm/pseudoaneurysm/megafistula'</a>.)</p><p class="headingAnchor" id="H3251449032"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Although not always the case, clinical manifestations of problems caused by a high blood flow rate (Qa) generally begin with minimal signs and symptoms but tend to be progressive. Early diagnosis and management are important. An enlarging AV fistula may not be noted because the change is gradual. Enlarging aneurysms may be simply attributed to poor cannulation technique. Even serious complications such as high-output cardiac failure and pulmonary edema are underdiagnosed because the dialysis treatment removes fluid and masks early signs and symptoms. For these reasons, a high index of suspicion is important so that the goal of early diagnosis and management can be achieved.</p><p>An excessive Qa should be suspected in any patient who develops any of the clinical manifestations listed below (discussed in further detail above and in associated topics). (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Eccentric left ventricular hypertrophy. (See <a class="local">'Eccentric left ventricular hypertrophy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-output cardiac failure. (See <a class="local">'High-output cardiac failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial ischemia. (See <a class="local">'Myocardial ischemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension. (See <a class="local">'Pulmonary hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemodialysis access-induced distal ischemia. (See <a class="local">'Hemodialysis access-induced distal ischemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased dialysis clearance secondary to high cardiopulmonary recirculation. (See <a class="local">'Decreased dialysis clearance secondary to high cardiopulmonary recirculation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral and central venous stenosis. (See <a class="local">'Accelerated central or peripheral venous stenosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aneurysmal enlargement of the access (megafistula  (<a class="graphic graphic_picture graphicRef117563" href="/d/graphic/117563.html" rel="external">picture 2</a>)), aneurysm/pseudoaneurysms. (See <a class="local">'Aneurysmal enlargement of the AV access'</a> above.)</p><p></p><p class="headingAnchor" id="H1697127103"><span class="h2">Physical examination of the access</span><span class="headingEndMark"> — </span>While the measured Qa is the defining feature for defining an AV access with an excessively high Qa, at least a suspicion of the problem can be ascertained by a careful physical examination of the access. Typically, high Qa is much more common in association with an AV fistula compared with an AV graft and more commonly seen in AV access of the upper arm. </p><p>The AV fistula in these cases is generally quite large. While not hyperpulsatile unless there is a significant downstream obstruction, the thrill and bruit are continuous and more prominent in the high-flow AV access than in an access with a lower Qa. Normally, as one progresses up the vein, the prominence of the background thrill and bruit becomes somewhat less. With a high-flow Qa access, this is not the case. </p><p>When the normal-flow AV fistula is associated with a significant downstream stenosis, the access is markedly hyperpulsatile. The thrill is shortened and may be systolic only. This is also true for the bruit, which may also increase in pitch, at times taking on a whistling character. In the high-flow AV fistula with a downstream obstruction, the most obvious physical finding is the large size of the access. The fistula is hyperpulsatile but may not be to the degree noted in an AV fistula with a normal Qa because of the increased diameter of the vessel. The thrill and bruit tend to be longer and in some cases may be continuous [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1210533638"><span class="h2">Radiographic appearance</span><span class="headingEndMark"> — </span>The key to distinguishing between the high-flow Qa and normal Qa access lies in recognition of the diameter of the vessel at the site of narrowing compared with the adjacent "normal" vessel. Practice guidelines recommend that a lesion should represent a 50 percent stenosis to justify treatment. An access having a diameter of 8 mm with a narrowed zone of 4 mm and an access of 14 mm with a narrowing of 7 mm both represent 50 percent stenosis. However, the latter case would suggest an inflow problem (high Qa), while the former would suggest an outflow problem. Optimal treatment of the two cases would be different: angioplasty versus flow reduction.</p><p class="headingAnchor" id="H204987329"><span class="h2">Access flow measurement</span><span class="headingEndMark"> — </span>The diagnosis of a high Qa is dependent upon its measurement. This can be easily quantitated using Doppler ultrasound. Measurement should be made from the brachial artery at least 5 cm proximal to the anastomosis regardless of whether one is dealing with a radial or brachial artery-based AV fistula [<a href="#rid7">7,47-50,56-60</a>]. In cases of high bifurcation of the brachial artery, the measurement should be made from the brachial artery proximal to the bifurcation. Blood flow measurements made from the access itself are fraught with errors because of the variation in the diameter of the access and its easy compressibility. The brachial artery measurement overestimates the Qa in that it includes that which perfuses the hand; however, this amount is not enough to materially affect decisions made relating to management. Since Qa is directly proportional to the mean inflow blood pressure [<a href="#rid61">61</a>], clinical judgment is necessary in dealing with patients with a systemic blood pressure that is either high or low.</p><p class="headingAnchor" id="H1245531266"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The sequelae resulting from the various problems caused by a high blood flow rate (Qa) range from those that can affect the efficiency of dialysis or the viability of the vascular access to those that can result in the loss of a digit or endanger the life of the patient. For this reason, clinical judgment and consideration of the severity of the patient's individual condition is critical. Treatment is individualized based on the clinical presentation, including patient comorbidities, symptoms, and projected longevity. </p><p class="headingAnchor" id="H1479798476"><span class="h2">Flow reduction</span><span class="headingEndMark"> — </span>The ideal goal of treatment is to alleviate adverse effects by reducing Qa (ie, flow reduction) while preserving the AV access. Even when dealing with the more serious complications such as high-output cardiac failure, pulmonary hypertension, and hemodialysis access-induced distal ischemia (HAIDI), this goal can generally be achieved if treatment is instituted early. Most patients with severe manifestations of high Qa will require AV access ligation.</p><p class="headingAnchor" id="H453439460"><span class="h3">General considerations</span><span class="headingEndMark"> — </span>Treatment criteria for flow reduction for conditions such as cardiopulmonary disease (heart failure, pulmonary hypertension, hemodialysis access-induced distal ischemia) associated with excessively high Qa are well documented.<strong> </strong>Beyond these conditions, criteria for treatment are less well defined. (See  <a class="medical medical_review" href="/d/html/112442.html" rel="external">"Pulmonary hypertension in patients with end-stage kidney disease"</a> and  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a> and  <a class="medical medical_review" href="/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia"</a>.)</p><p>For patients with venous stenosis associated with a hemodialysis AV access, clinical manifestations are the result of an inflow-outflow imbalance. Qa can be normal, low, or high. When the Qa is high, flow reduction rather than angioplasty should be performed.<strong> </strong>When angioplasty is used to treat a stenotic lesion, Qa can be expected to increase (except for treatment of a central venous stenosis) [<a href="#rid62">62</a>]. In patients with either a marginal or a high Qa, this increased flow following angioplasty can worsen or precipitate problems such as heart failure, pulmonary edema, or hand ischemia [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H3602115960"><span class="h3">Target flow rate</span><span class="headingEndMark"> — </span>There is no generally accepted target value for flow reduction. The goal is to reduce Qa to the maximal degree possible without risking the loss of patency. Some studies have used levels of 800 mL/min for an AV fistula and 1000 mL/min for an AV graft as threshold levels for a patient with a normal blood pressure [<a href="#rid7">7,64</a>]. In other reports, Qa has been reduced to levels below this. In a report of 398 cases of precision banding, the target for intraprocedural Qa for AV fistulas was in the 400 to 600 mL/min range and 600 to 800 mL/min in AV grafts [<a href="#rid65">65</a>]. Some degree of rebound post-banding was observed, which was less pronounced in AV grafts. Even when reduced to these levels, post-banding access patency rates have been reasonably good [<a href="#rid16">16,17,65</a>]. These Qa levels are adequate for efficient, effective dialysis. </p><p class="headingAnchor" id="H3146374125"><span class="h3">Options for flow reduction</span><span class="headingEndMark"> — </span>Three approaches are available for flow reduction, including ligation of a large venous tributaries, precision banding or its equivalent (surgical, endovascular), and revascularization procedures such as revision of distal inflow (RUDI)  (<a class="graphic graphic_figure graphicRef76970" href="/d/graphic/76970.html" rel="external">figure 2</a>) [<a href="#rid66">66-68</a>].</p><p class="headingAnchor" id="H2364924982"><span class="h4">Ligation of venous tributaries</span><span class="headingEndMark"> — </span>Venous tributaries associated with an AV fistula have an additive effect on Qa volume. Limited studies have shown that in cases demonstrating this type of vascular anatomy, ligation of these contributing veins may be effective in relieving the symptoms of hand ischemia [<a href="#rid69">69</a>]. </p><p>However, it should be noted that there are limitations to this approach. Large tributaries are not commonly seen with either brachial-cephalic or brachial-basilic AV fistulas. Reports advocating ligation of these veins have primarily dealt with Gracz AV fistulas, so this method of flow reduction may be somewhat specific to that type of access.</p><p>The role large venous tributaries might play in the pathogenesis of hand ischemia associated with a radial-cephalic fistula has not been studied. </p><p class="headingAnchor" id="H2385590853"><span class="h4">Precision banding</span><span class="headingEndMark"> — </span>Although other banding techniques have been used in the past, the standard of practice is termed "precision-banding." This technique is safe and effective and can be easily done and undone until the desired Qa volume reduction is achieved, or repeated, as needed. The procedure is accomplished by using a sizing device placed intraluminally or extraluminally to ensure that a controlled degree of luminal restriction is achieved [<a href="#rid70">70-72</a>]. For this purpose, an intravascular dilator or angioplasty balloon is generally used. However, there are reports of instances in which an angioplasty balloon has been partially compressed by tying the ligature too tightly, creating a risk of thrombosis [<a href="#rid65">65</a>]. To ensure success, accurate intraoperative Doppler ultrasound flow measurements to judge the degree of access flow restriction should be considered mandatory [<a href="#rid17">17,70,73</a>]. In one report, significant changes in Qa were noted, with only 0.5 mm variations in lumen diameter achieved with banding [<a href="#rid70">70</a>]. </p><p>In selecting an intraoperative post-banding Qa, the relationship between blood flow and blood pressure must be taken into consideration. The values quoted in these recommendations are based upon a normalized blood pressure maintained during the procedure for the final Qa measurement. Since the effect of a stenotic lesion on Qa is directly proportional to the mean inflow pressure [<a href="#rid61">61</a>], clinical judgment is necessary in dealing with patients with a systemic blood pressure that is either high or low.</p><p class="headingAnchor" id="H329264717"><span class="h4">Revision using distal inflow</span><span class="headingEndMark"> — </span>The RUDI procedure  (<a class="graphic graphic_figure graphicRef76970" href="/d/graphic/76970.html" rel="external">figure 2</a>) is based upon the concept that a radial artery-based access is associated with a lower Qa than one associated with the brachial artery. The RUDI procedure is accomplished by closing the original AV anastomosis with the distal brachial artery and moving it to the more distal proximal radial or ulnar artery. This can be accomplished either by direct anastomosis of the outflow vein to the new inflow artery if possible or with an interposition graft (saphenous vein or expanded polytetrafluoroethylene [ePTFE]) [<a href="#rid74">74,75</a>]. </p><p class="headingAnchor" id="H2488742548"><span class="h3">Outcomes of flow reduction</span><span class="headingEndMark"> — </span>As indicated above, flow reduction is not successful in all cases initially or in longer-term follow-up. However, in most cases it is effective in either improving or eliminating the clinical signs and symptoms of the condition for which it was performed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiopulmonary</strong> – For patients with cardiac or pulmonary manifestations, flow reduction improves heart structure and function and reduces pulmonary artery pressure [<a href="#rid76">76-78</a>]. Beneficial effects of flow reduction are present even in patients without symptoms of heart failure. Symptomatic and structural improvements have been noted within weeks of the procedure [<a href="#rid70">70,77</a>]. (See  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a>.)</p><p></p><p class="bulletIndent1">There are no studies available assessing the effect of flow reduction on myocardial ischemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hand ischemia</strong> – Hemodialysis access-induced distal ischemia (HAIDI) can be associated with high, normal, or low flow, which determines treatment  (<a class="graphic graphic_algorithm graphicRef122924" href="/d/graphic/122924.html" rel="external">algorithm 1</a>). For cases related to high flow, flow reduction has a high degree of success in relieving symptoms of hand ischemia [<a href="#rid9">9,79,80</a>]. In a review of surgical techniques used to treat HAIDI associated with high flow, 12 studies involving 255 cases used precision banding [<a href="#rid80">80</a>]. The pooled rate for symptomatic relief was 90.2 percent (95% CI 80.5 to 97.3 percent), and early thrombosis of the vascular access was 8.2 percent (95% CI 0.6 to 20.4 percent). The surgical procedure RUDI, in which the anastomosis of a brachial artery associated with upper arm access is moved distally to the proximal radial or ulnar artery, has also been used to treat a high Qa-associated HAIDI. In the study referred to above [<a href="#rid80">80</a>], only two reports were found, involving 26 cases. The pooled rate for symptomatic relief was 93.1 percent, and early thrombosis of the vascular access was 12.1 percent. (See  <a class="medical medical_review" href="/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral and central venous stenosis</strong> — The literature as it relates to this complication associated with high Qa consists of only a few small case series reports. Flow reduction in these cases has been prompted by the frequency of symptomatic recurrence of these lesions after successful treatment, especially the cephalic arch and central veins. The benefit of the procedure has been judged by a significant decrease in the frequency of recurrence [<a href="#rid81">81,82</a>]. (See  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access"</a> and  <a class="medical medical_review" href="/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decrease dialysis clearance secondary to high cardiopulmonary recirculation</strong> — There are no publications available that address this problem directly. In a study of 10 patients with high-output cardiac function who underwent surgical flow reduction [<a href="#rid77">77</a>], Qa (adjusted to L/min/1.73 m<sup>2</sup>) was 2.4 before the procedure and was reduced after the procedure to 0.9. Cardiopulmonary resuscitation (CPR) dropped from 41 to 16 percent at one month. Although the effect on dialysis clearance was not assessed, this problem is related to a high CPR. With this decrease, the cause for the problem would have been removed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomical abnormalities of vascular access</strong> — Although a high Qa plays a role in the formation and progression of aneurysms, pseudoaneurysms, and vascular ectasia, removing the stimulus by reducing Qa does not result in regression. With the removal of the stimulus, the further advancement is only arrested. (See  <a class="medical medical_review" href="/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications", section on 'Aneurysm/pseudoaneurysm/megafistula'</a>.)</p><p></p><p class="headingAnchor" id="H3302016819"><span class="h2">AV access ligation</span><span class="headingEndMark"> — </span>Some patients present with severe symptoms, and for others the situation is not recognized until signs and symptoms have advanced to a critical state. In these patients, access ligation, rather than attempts at flow reduction, may be required. </p><p>It should be noted that a patient with severe cardiopulmonary disease has a short life expectancy, and dialysis therapy is palliative. In these situations, hemodialysis with a central venous catheter or peritoneal dialysis represents the best choice. </p><p class="headingAnchor" id="H3153939145"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>After flow reduction, patient follow-up is important to determine the course of the patient's symptoms. If symptoms improve, the patient should continue to be monitored. The interval for evaluation should be determined by the patient's individual situation. </p><p class="headingAnchor" id="H1940708591"><span class="h2">Repeat banding</span><span class="headingEndMark"> — </span>Experience with precision banding for flow reduction has shown a small but significant incidence of thrombosis as well as a small but significant incidence of cases requiring rebanding. In a large study of precision banding, target for intraprocedural blow flow rate (Qa) for AV fistulas was in the 400 to 600 mL/min range and 600 to 800 mL/min in AV grafts [<a href="#rid65">65</a>]. With a median follow-up of 157 days (range 52 to 373 days), rebanding was required in 54 of 398 cases (14 percent), with the median time to rebanding of 134 days (range 56 to 224 days). Early banding failure occurred in 9/398 (2.3 percent) of patients, typically associated with an increase of the angiographic diameter at the banding site postprocedure to rebanding, suggesting that the knots of the banding suture had slipped. The 30-day thrombosis rate after banding was 15 of 397 cases (3.8 percent), with a median time to event of 5.5 days (range 2 to 102 days).</p><p class="headingAnchor" id="H3613464345"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>If symptoms do not improve after flow reduction in those treated for cardiopulmonary disease, the access should be ligated. In general, these patients have a short life expectancy, and dialysis treatments are palliative. </p><p>For the patient with HAIDI, an alternative surgical procedure to salvage the access may be possible. If not, the access should be ligated. In these patients, if dialysis is to be continued, the creation of a new AV access may be possible after a detailed clinical evaluation. </p><p class="headingAnchor" id="H1771501641"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of AV access flow</strong> – Arteriovenous (AV) vascular access is necessary for the delivery of lifesaving hemodialysis therapy but is nonphysiologic. The increased blood flow generated by the AV access increases the workload of the cardiopulmonary system and reduces flow to the hand. While compensatory mechanisms reduce some of these effects, excessive blood flow rate (Qa) can cause serious complications, some of which can be life- or limb-threatening. Thus, early recognition and management of the high-flow AV access is an important aspect of medical care delivered to the hemodialysis patient. (See <a class="local">'Introduction'</a> above and <a class="local">'High-flow arteriovenous access'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of high flow</strong> – A high-flow AV access can be defined as having a Qa &gt;1500 mL/min, or Qa &gt;20 percent of the cardiac output (ie, cardiopulmonary circulation [CPR] &gt;20 percent) has been suggested. However, the exact threshold for defining a high Qa access has not been rigorously validated nor universally accepted. Patients with specifically related comorbidities can develop adverse sequelae from a Qa below these levels. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> <strong>for high-flow AV access</strong> – High Qa is more commonly seen in association with an AV fistula than with an AV graft. Brachial-cephalic and brachial-basilic AV accesses are much more commonly associated with this problem compared with distal radial-cephalic AV access. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Clinical manifestations of high Qa are generally related to the development of, or worsening of, cardiopulmonary dysfunction or distal ischemia. Clinical manifestations generally begin with minimal symptoms and signs but tend to be progressive. A careful physical examination of the AV access may help confirm a suspicion. Excessive Qa should be suspected in any patient who develops any of the clinical manifestations listed below. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-output cardiac failure</strong> – High-output cardiac failure (HOCF) results when Qa exceeds the patient's cardiac functional reserve. HOCF is characterized by dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and edema (pulmonary, peripheral) in the presence of an above-normal cardiac index or simply an elevated cardiac output.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary hypertension</strong> – The increase in cardiac output following AV access creation is accompanied by an increase in pulmonary arterial pressure, which correlates with Qa. Pulmonary hypertension is characterized by progressive dyspnea, fatigue, syncope, and signs of right heart failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodialysis access-induced distal ischemia</strong> – Hemodialysis access-induced distal ischemia (HAIDI) can occur due to decreased perfusion pressure occurring distal to the AV access anastomosis. While compensatory mechanisms counteract this adverse effect, ischemia can result in significant limb dysfunction or even limb loss. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aneurysmal enlargement of the AV access</strong> – Increased flow proportionally increases wall shear stress, which promotes vasodilatation and remodeling of the vein to increase diameter. Further diameter increases can result from downstream venous stenosis. The result can be a diffusely ectatic, tortuous AV fistula commonly referred to as a "megafistula."</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – Other manifestations may include eccentric left ventricular hypertrophy, myocardial ischemia, reduced efficiency of hemodialysis from cardiopulmonary circulation, and peripheral or central venous stenosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of a high Qa relies on flow measurement, which is performed using ultrasound. The measurement is made from the brachial artery at least 5 cm proximal to the AV access anastomosis, rather than from the access itself. Since Qa is directly proportional to the mean inflow blood pressure, clinical judgment is necessary in determining if Qa is high in patients with higher or lower than normal blood pressure. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management of high Qa is individualized based on the clinical presentation and including patient comorbidities, symptoms, and anticipated lifespan. In general (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with severe manifestations of high Qa will require AV access ligation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all other symptomatic patients, we suggest a flow reduction procedure, rather than AV access ligation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with persistent cardiopulmonary symptoms following flow reduction, we ligate the AV access. However, for patients with HAIDI, an alternative surgical procedure to salvage the access may be possible before consideration of AV access ligation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flow reduction</strong> – Flow reduction aims to alleviate symptoms by reducing flow while preserving the AV access. This goal can generally be achieved if treatment is instituted early even when dealing with serious clinical manifestations. Flow reduction effectively improves or eliminates the clinical signs and symptoms associated with high Qa. (See <a class="local">'Flow reduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target flow rate</strong> – There is no generally accepted target value for flow reduction. The goal is to reduce Qa to the degree possible without risking loss of AV access patency. Some studies have used levels of 800 mL/min for an AV fistula and 1000 mL/min for an AV graft as threshold levels for a patient with a normal blood pressure. Using these values, post-banding access patency rates have been reasonably good. (See <a class="local">'Target flow rate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Options for flow reduction</strong> – Three approaches are available for flow reduction, including precision banding or its equivalent (surgical, endovascular), ligation of large venous tributaries, and revascularization procedures such as revision using distal inflow (RUDI)  (<a class="graphic graphic_figure graphicRef76970" href="/d/graphic/76970.html" rel="external">figure 2</a>). Rebanding is an option for initial banding failures. (See <a class="local">'Options for flow reduction'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Amerling R. Con: on cardiovascular outcomes and the arteriovenous fistula: lesser of evils. Nephrol Dial Transplant 2012; 27:3756.</a></li><li><a class="nounderline abstract_t">Basile C, Lomonte C. The complex relationship among arteriovenous access, heart, and circulation. Semin Dial 2018; 31:15.</a></li><li><a class="nounderline abstract_t">Sequeira A, Tan TW. Complications of a High-flow Access and Its Management. Semin Dial 2015; 28:533.</a></li><li><a class="nounderline abstract_t">Bansal N, Roy J, Chen HY, et al. Evolution of Echocardiographic Measures of Cardiac Disease From CKD to ESRD and Risk of All-Cause Mortality: Findings From the CRIC Study. Am J Kidney Dis 2018; 72:390.</a></li><li><a class="nounderline abstract_t">House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:1304.</a></li><li><a class="nounderline abstract_t">Alkhouli M, Sandhu P, Boobes K, et al. Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease. Nefrologia 2015; 35:234.</a></li><li><a class="nounderline abstract_t">Beathard GA, Lok CE, Glickman MH, et al. Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. Clin J Am Soc Nephrol 2018; 13:501.</a></li><li><a class="nounderline abstract_t">Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23:282.</a></li><li><a class="nounderline abstract_t">Aitken E, Kerr D, Geddes C, et al. Cardiovascular changes occurring with occlusion of a mature arteriovenous fistula. J Vasc Access 2015; 16:459.</a></li><li><a class="nounderline abstract_t">Lomonte C, Casucci F, Antonelli M, et al. Is there a place for duplex screening of the brachial artery in the maturation of arteriovenous fistulas? Semin Dial 2005; 18:243.</a></li><li><a class="nounderline abstract_t">Yigla M, Abassi Z, Reisner SA, Nakhoul F. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19:353.</a></li><li><a class="nounderline abstract_t">Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123:1577.</a></li><li><a class="nounderline abstract_t">Acarturk G, Albayrak R, Melek M, et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients. Int Urol Nephrol 2008; 40:509.</a></li><li><a class="nounderline abstract_t">Roca-Tey R, Rivas A, Samón R, et al. [Noninvasive assessment of forearm vessels by color Doppler ultrasonography (CDU) before and after radiocephalic fistula (RCF) placement]. Nefrologia 2007; 27:489.</a></li><li><a class="nounderline abstract_t">Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17:S1.</a></li><li><a class="nounderline abstract_t">Aschwanden M, Hess P, Labs KH, et al. Dialysis access-associated steal syndrome: the intraoperative use of duplex ultrasound scan. J Vasc Surg 2003; 37:211.</a></li><li><a class="nounderline abstract_t">Zanow J, Petzold K, Petzold M, et al. Flow reduction in high-flow arteriovenous access using intraoperative flow monitoring. J Vasc Surg 2006; 44:1273.</a></li><li><a class="nounderline abstract_t">Miller GA, Hwang WW. Challenges and management of high-flow arteriovenous fistulae. Semin Nephrol 2012; 32:545.</a></li><li><a class="nounderline abstract_t">Faull R, Rao N, Worthley M. Do arteriovenous fistulas increase cardiac risk? Semin Dial 2018; 31:357.</a></li><li><a class="nounderline abstract_t">Albayrak R, Yuksel S, Colbay M, et al. Hemodynamic changes in the cephalic vein of patients with hemodialysis arteriovenous fistula. J Clin Ultrasound 2007; 35:133.</a></li><li><a class="nounderline abstract_t">Martínez-Gallardo R, Ferreira-Morong F, García-Pino G, et al. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. Nefrologia 2012; 32:206.</a></li><li><a class="nounderline abstract_t">Rigatto C, Foley R, Jeffery J, et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14:462.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Harnett JD, Griffiths SM, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990; 55:114.</a></li><li><a class="nounderline abstract_t">London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17 Suppl 1:29.</a></li><li><a class="nounderline abstract_t">Savage MT, Ferro CJ, Sassano A, Tomson CR. The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: a prospective study. Am J Kidney Dis 2002; 40:753.</a></li><li><a class="nounderline abstract_t">Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20:1686.</a></li><li><a class="nounderline abstract_t">Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974.</a></li><li><a class="nounderline abstract_t">Stoumpos S, Rankin A, Hall Barrientos P, et al. Interrogating the haemodynamic effects of haemodialysis arteriovenous fistula on cardiac structure and function. Sci Rep 2021; 11:18102.</a></li><li><a class="nounderline abstract_t">Ori Y, Korzets A, Katz M, et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. Am J Kidney Dis 2002; 40:745.</a></li><li><a class="nounderline abstract_t">Wytrzes L, Markley HG, Fisher M, Alfred HJ. Brachial neuropathy after brachial artery-antecubital vein shunts for chronic hemodialysis. Neurology 1987; 37:1398.</a></li><li><a class="nounderline abstract_t">Redfern AB, Zimmerman NB. Neurologic and ischemic complications of upper extremity vascular access for dialysis. J Hand Surg Am 1995; 20:199.</a></li><li><a class="nounderline abstract_t">Isoda S, Kajiwara H, Kondo J, Matsumoto A. Banding a hemodialysis arteriovenous fistula to decrease blood flow and resolve high output cardiac failure: report of a case. Surg Today 1994; 24:734.</a></li><li><a class="nounderline abstract_t">Young PR Jr, Rohr MS, Marterre WF Jr. High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases. Am Surg 1998; 64:239.</a></li><li><a class="nounderline abstract_t">MacRae JM, Pandeya S, Humen DP, et al. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 2004; 43:e17.</a></li><li><a class="nounderline abstract_t">Wasse H, Singapuri MS. High-output heart failure: how to define it, when to treat it, and how to treat it. Semin Nephrol 2012; 32:551.</a></li><li><a class="nounderline abstract_t">Engelberts I, Tordoir JH, Boon ES, Schreij G. High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis. Am J Nephrol 1995; 15:323.</a></li><li><a class="nounderline abstract_t">Hakeem A, Bhatti S, Chang SM. Screening and risk stratification of coronary artery disease in end-stage renal disease. JACC Cardiovasc Imaging 2014; 7:715.</a></li><li><a class="nounderline abstract_t">MacRae JM, Levin A, Belenkie I. The cardiovascular effects of arteriovenous fistulas in chronic kidney disease: a cause for concern? Semin Dial 2006; 19:349.</a></li><li><a class="nounderline abstract_t">Pabst S, Hammerstingl C, Hundt F, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One 2012; 7:e35310.</a></li><li><a class="nounderline abstract_t">Abassi Z, Nakhoul F, Khankin E, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15:353.</a></li><li><a class="nounderline abstract_t">Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant 2012; 27:3908.</a></li><li><a class="nounderline abstract_t">Ramasubbu K, Deswal A, Herdejurgen C, et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med 2010; 3:279.</a></li><li><a class="nounderline abstract_t">Abedini M, Sadeghi M, Naini AE, et al. Pulmonary hypertension among patients on dialysis and kidney transplant recipients. Ren Fail 2013; 35:560.</a></li><li><a class="nounderline abstract_t">Etemadi J, Zolfaghari H, Firoozi R, et al. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients. Rev Port Pneumol 2012; 18:10.</a></li><li><a class="nounderline abstract_t">Clarkson MR, Giblin L, Brown A, et al. Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. Am J Kidney Dis 2002; 40:E8.</a></li><li><a class="nounderline abstract_t">Fabbian F. [Should pulmonary artery pressure be evaluated in uremic patients?]. G Ital Nefrol 2011; 28:356.</a></li><li><a class="nounderline abstract_t">Ferring M, Henderson J, Wilmink T. Accuracy of early postoperative clinical and ultrasound examination of arteriovenous fistulae to predict dialysis use. J Vasc Access 2014; 15:291.</a></li><li><a class="nounderline abstract_t">Jemcov TK. Morphologic and functional vessels characteristics assessed by ultrasonography for prediction of radiocephalic fistula maturation. J Vasc Access 2013; 14:356.</a></li><li><a class="nounderline abstract_t">Besarab A, Sherman R. The relationship of recirculation to access blood flow. Am J Kidney Dis 1997; 29:223.</a></li><li><a class="nounderline abstract_t">Wiese P, Nonnast-Daniel B. Colour Doppler ultrasound in dialysis access. Nephrol Dial Transplant 2004; 19:1956.</a></li><li><a class="nounderline abstract_t">Remuzzi A, Ene-Iordache B. Novel paradigms for dialysis vascular access: upstream hemodynamics and vascular remodeling in dialysis access stenosis. Clin J Am Soc Nephrol 2013; 8:2186.</a></li><li><a class="nounderline abstract_t">Lee T, Somarathna M, Hura A, et al. Natural history of venous morphologic changes in dialysis access stenosis. J Vasc Access 2014; 15:298.</a></li><li><a class="nounderline abstract_t">MacRae JM, Ahmed A, Johnson N, et al. Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J 2005; 51:77.</a></li><li><a class="nounderline abstract_t">Oguzkurt L, Tercan F, Yildirim S, Torun D. Central venous stenosis in haemodialysis patients without a previous history of catheter placement. Eur J Radiol 2005; 55:237.</a></li><li><a class="nounderline abstract_t">Taal MW, Chesterton LJ, McIntyre CW. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis. Nephrol Dial Transplant 2004; 19:1542.</a></li><li><a class="nounderline abstract_t">Scaffaro LA, Bettio JA, Cavazzola SA, et al. Maintenance of hemodialysis arteriovenous fistulas by an interventional strategy: clinical and duplex ultrasonographic surveillance followed by transluminal angioplasty. J Ultrasound Med 2009; 28:1159.</a></li><li><a class="nounderline abstract_t">van Hooland S, Malik J. Hemodialysis vascular access ultrasonography: tips, tricks, pitfalls and a quiz. J Vasc Access 2010; 11:255.</a></li><li class="breakAll">Malovrh, M. Emerging role of vascular ultrasound in arteriovenous dialysis access, McGraw Hill Medica, New York 2012.</li><li><a class="nounderline abstract_t">Chowdhury S, Goss D, Mistry H, et al. Duplex ultrasound volumetric flow analysis before and after hemodialysis in patients with brachio-cephalic fistulae. J Vasc Access 2013; 14:342.</a></li><li><a class="nounderline abstract_t">Zhu YL, Ding H, Fan PL, et al. Predicting the maturity of haemodialysis arteriovenous fistulas with colour Doppler ultrasound: a single-centre study from China. Clin Radiol 2016; 71:576.</a></li><li><a class="nounderline abstract_t">Dodds SR. The haemodynamics of asymmetric stenoses. Eur J Vasc Endovasc Surg 2002; 24:332.</a></li><li><a class="nounderline abstract_t">Yan Y, Sudheendra D, Dagli MS, et al. Effect of central venous angioplasty on hemodialysis access circuit flow: prospective study of 25 symptomatic patients. J Vasc Interv Radiol 2015; 26:984.</a></li><li><a class="nounderline abstract_t">Vélez-Martínez M, Weinberg BD, Mishkin JD. Flash pulmonary oedema after relief of haemodialysis graft stenosis. Heart Lung Circ 2013; 22:672.</a></li><li><a class="nounderline abstract_t">Beathard GA, Spergel LM. Hand ischemia associated with dialysis vascular access: an individualized access flow-based approach to therapy. Semin Dial 2013; 26:287.</a></li><li class="breakAll">Soo Hoo, AJ, Scully, RE, Sharma, G, et al. Contemporary outcomes of precision banding for high flow hemodialysis access. J Vasc Access 2022:11297298221076581.</li><li><a class="nounderline abstract_t">Malik J, Tuka V, Kasalova Z, et al. Understanding the dialysis access steal syndrome. A review of the etiologies, diagnosis, prevention and treatment strategies. J Vasc Access 2008; 9:155.</a></li><li><a class="nounderline abstract_t">Inston N, Schanzer H, Widmer M, et al. Arteriovenous access ischemic steal (AVAIS) in haemodialysis: a consensus from the Charing Cross Vascular Access Masterclass 2016. J Vasc Access 2017; 18:3.</a></li><li><a class="nounderline abstract_t">Davidson I, Beathard G, Gallieni M, Ross J. The DRIL procedure for arteriovenous access ischemic steal: a controversial approach. J Vasc Access 2017; 18:1.</a></li><li><a class="nounderline abstract_t">Vaes RH, Wouda R, Teijink JA, Scheltinga MR. Venous Side Branch Ligation as a First Step Treatment for Haemodialysis Access Induced Hand Ischaemia: Effects on Access Flow Volume and Digital Perfusion. Eur J Vasc Endovasc Surg 2015; 50:810.</a></li><li><a class="nounderline abstract_t">Gkotsis G, Jennings WC, Malik J, et al. Treatment of High Flow Arteriovenous Fistulas after Successful Renal Transplant Using a Simple Precision Banding Technique. Ann Vasc Surg 2016; 31:85.</a></li><li><a class="nounderline abstract_t">Miller GA, Friedman A, Khariton A, et al. Access flow reduction and recurrent symptomatic cephalic arch stenosis in brachiocephalic hemodialysis arteriovenous fistulas. J Vasc Access 2010; 11:281.</a></li><li><a class="nounderline abstract_t">Wang S, Almehmi A, Asif A. Surgical management of cephalic arch occlusive lesions: are there predictors for outcomes? Semin Dial 2013; 26:E33.</a></li><li><a class="nounderline abstract_t">Scheltinga MR, Van Hoek F, Bruyninckx CM. Surgical banding for refractory hemodialysis access-induced distal ischemia (HAIDI). J Vasc Access 2009; 10:43.</a></li><li><a class="nounderline abstract_t">Minion DJ, Moore E, Endean E. Revision using distal inflow: a novel approach to dialysis-associated steal syndrome. Ann Vasc Surg 2005; 19:625.</a></li><li><a class="nounderline abstract_t">Loh TM, Bennett ME, Peden EK. Revision using distal inflow is a safe and effective treatment for ischemic steal syndrome and pathologic high flow after access creation. J Vasc Surg 2016; 63:441.</a></li><li><a class="nounderline abstract_t">Rao NN, Stokes MB, Rajwani A, et al. Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients. Circulation 2019; 139:2809.</a></li><li><a class="nounderline abstract_t">Maresca B, Filice FB, Orlando S, et al. Early echocardiographic modifications after flow reduction by proximal radial artery ligation in patients with high-output heart failure due to high-flow forearm arteriovenous fistula. J Vasc Access 2020; 21:753.</a></li><li><a class="nounderline abstract_t">Salehi T, Montarello NJ, Juneja N, et al. Long-Term Impact of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients: A 5-Year Follow-Up Observational Cohort Study. Kidney360 2021; 2:1141.</a></li><li><a class="nounderline abstract_t">Miller GA, Goel N, Friedman A, et al. The MILLER banding procedure is an effective method for treating dialysis-associated steal syndrome. Kidney Int 2010; 77:359.</a></li><li><a class="nounderline abstract_t">Cooper MW, Stanbaugh GH, Walling SB, et al. Effects of occlusion of fistulae on left ventricular dimensions in hemodialysis patients. Trans Am Soc Artif Intern Organs 1981; 27:625.</a></li><li><a class="nounderline abstract_t">Teixeira G, Almeida P, Sousa CN, et al. Arteriovenous access banding revisited. J Vasc Access 2017; 18:225.</a></li><li><a class="nounderline abstract_t">Al Shakarchi J, Stolba J, Houston JG, Inston N. Surgical techniques for haemodialysis access-induced distal ischaemia. J Vasc Access 2016; 17:40.</a></li></ol></div><div id="topicVersionRevision">Topic 15074 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114902" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Con: on cardiovascular outcomes and the arteriovenous fistula: lesser of evils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28990213" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The complex relationship among arteriovenous access, heart, and circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25808428" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complications of a High-flow Access and Its Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29784617" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evolution of Echocardiographic Measures of Cardiac Disease From CKD to ESRD and Risk of All-Cause Mortality: Findings From the CRIC Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053387" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299166" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729383" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942475" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634156" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cardiovascular changes occurring with occlusion of a mature arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934972" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Is there a place for duplex screening of the brachial artery in the maturation of arteriovenous fistulas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970730" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary hypertension in hemodialysis patients: an unrecognized threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12740276" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pulmonary hypertension in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17985208" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17944587" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : [Noninvasive assessment of forearm vessels by color Doppler ultrasonography (CDU) before and after radiocephalic fistula (RCF) placement].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497879" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514605" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dialysis access-associated steal syndrome: the intraoperative use of duplex ultrasound scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145429" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Flow reduction in high-flow arteriovenous access using intraoperative flow monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217334" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Challenges and management of high-flow arteriovenous fistulae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29513901" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Do arteriovenous fistulas increase cardiac risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17274035" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hemodynamic changes in the cephalic vein of patients with hemodialysis arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425802" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538748" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2141918" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The clinical course of left ventricular hypertrophy in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812909" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Left ventricular alterations and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324910" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840664" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407642" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34518583" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interrogating the haemodynamic effects of haemodialysis arteriovenous fistula on cardiac structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324909" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3039408" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Brachial neuropathy after brachial artery-antecubital vein shunts for chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7775751" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neurologic and ischemic complications of upper extremity vascular access for dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7981545" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Banding a hemodialysis arteriovenous fistula to decrease blood flow and resolve high output cardiac failure: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9520814" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15112194" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217335" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High-output heart failure: how to define it, when to treat it, and how to treat it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573191" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034921" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Screening and risk stratification of coronary artery disease in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970729" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The cardiovascular effects of arteriovenous fistulas in chronic kidney disease: a cause for concern?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22530005" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775448" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290987" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21042428" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23438072" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pulmonary hypertension among patients on dialysis and kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920698" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200825" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21809302" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Should pulmonary artery pressure be evaluated in uremic patients?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500848" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Accuracy of early postoperative clinical and ultrasound examination of arteriovenous fistulae to predict dialysis use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817950" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Morphologic and functional vessels characteristics assessed by ultrasonography for prediction of radiocephalic fistula maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9016893" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The relationship of recirculation to access blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15199165" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Colour Doppler ultrasound in dialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23990161" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Novel paradigms for dialysis vascular access: upstream hemodynamics and vascular remodeling in dialysis access stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500849" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Natural history of venous morphologic changes in dialysis access stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745139" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Central vein stenosis: a common problem in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16036153" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Central venous stenosis in haemodialysis patients without a previous history of catheter placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034155" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710213" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Maintenance of hemodialysis arteriovenous fistulas by an interventional strategy: clinical and duplex ultrasonographic surveillance followed by transluminal angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20658456" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemodialysis vascular access ultrasonography: tips, tricks, pitfalls and a quiz.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20658456" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hemodialysis vascular access ultrasonography: tips, tricks, pitfalls and a quiz.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23661143" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Duplex ultrasound volumetric flow analysis before and after hemodialysis in patients with brachio-cephalic fistulae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040802" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Predicting the maturity of haemodialysis arteriovenous fistulas with colour Doppler ultrasound: a single-centre study from China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12323176" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The haemodynamics of asymmetric stenoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890685" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of central venous angioplasty on hemodialysis access circuit flow: prospective study of 25 symptomatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253885" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Flash pulmonary oedema after relief of haemodialysis graft stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23581731" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hand ischemia associated with dialysis vascular access: an individualized access flow-based approach to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23581731" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hand ischemia associated with dialysis vascular access: an individualized access flow-based approach to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18850575" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Understanding the dialysis access steal syndrome. A review of the etiologies, diagnosis, prevention and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27739573" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Arteriovenous access ischemic steal (AVAIS) in haemodialysis: a consensus from the Charing Cross Vascular Access Masterclass 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27739574" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The DRIL procedure for arteriovenous access ischemic steal: a controversial approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26391963" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Venous Side Branch Ligation as a First Step Treatment for Haemodialysis Access Induced Hand Ischaemia: Effects on Access Flow Volume and Digital Perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26616507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of High Flow Arteriovenous Fistulas after Successful Renal Transplant Using a Simple Precision Banding Technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683832" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Access flow reduction and recurrent symptomatic cephalic arch stenosis in brachiocephalic hemodialysis arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458298" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Surgical management of cephalic arch occlusive lesions: are there predictors for outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19340799" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Surgical banding for refractory hemodialysis access-induced distal ischemia (HAIDI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052391" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Revision using distal inflow: a novel approach to dialysis-associated steal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492999" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Revision using distal inflow is a safe and effective treatment for ischemic steal syndrome and pathologic high flow after access creation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31045455" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32103699" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Early echocardiographic modifications after flow reduction by proximal radial artery ligation in patients with high-output heart failure due to high-flow forearm arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35368362" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-Term Impact of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients: A 5-Year Follow-Up Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010547" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The MILLER banding procedure is an effective method for treating dialysis-associated steal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7331144" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effects of occlusion of fistulae on left ventricular dimensions in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430308" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Arteriovenous access banding revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26349875" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Surgical techniques for haemodialysis access-induced distal ischaemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
